Davita (NYSE:DVA) and BioRestorative Therapies (OTCMKTS:BRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Davita and BioRestorative Therapies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Davita 0 5 4 0 2.44
BioRestorative Therapies 0 0 0 0 N/A

Davita presently has a consensus price target of $85.29, indicating a potential upside of 22.36%. Given Davita’s higher probable upside, equities analysts clearly believe Davita is more favorable than BioRestorative Therapies.

Risk & Volatility

Davita has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Earnings and Valuation

This table compares Davita and BioRestorative Therapies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Davita $10.88 billion 1.06 $663.61 million $3.32 20.99
BioRestorative Therapies $80,000.00 123.75 -$9.44 million N/A N/A

Davita has higher revenue and earnings than BioRestorative Therapies.

Institutional & Insider Ownership

87.4% of Davita shares are held by institutional investors. 1.0% of Davita shares are held by insiders. Comparatively, 43.2% of BioRestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Davita and BioRestorative Therapies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Davita 5.39% 13.87% 3.29%
BioRestorative Therapies -9,030.91% N/A -712.11%

Summary

Davita beats BioRestorative Therapies on 8 of the 11 factors compared between the two stocks.

About Davita

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

About BioRestorative Therapies

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.